Literature DB >> 22707013

Hepatitis B virus X protein modulates oncogene Yes-associated protein by CREB to promote growth of hepatoma cells.

Tao Zhang1, Junping Zhang, Xiaona You, Qian Liu, Yumei Du, Yuen Gao, Changliang Shan, Guangyao Kong, Youliang Wang, Xiao Yang, Lihong Ye, Xiaodong Zhang.   

Abstract

UNLABELLED: Hepatitis B virus X protein (HBx) plays critical roles in the development of hepatocellular carcinogenesis (HCC). Yes-associated protein (YAP), a downstream effector of the Hippo-signaling pathway, is an important human oncogene. In the present article, we report that YAP is involved in the hepatocarcinogenesis mediated by HBx. We demonstrated that the expression of YAP was dramatically elevated in clinical HCC samples, hepatitis B virus (HBV)-infected hepatoma HepG2.2.15 cell line, and liver cancer tissues of HBx-transgenic mice. Meanwhile, we found that overexpression of HBx resulted in the up-regulation of YAP in stably HBx-transfected HepG2/H7402 hepatoma cell lines, whereas HBx RNA interference reduced YAP expression in a dose-dependent manner in the above-mentioned cell lines, suggesting that HBx up-regulates YAP. Then, we investigated the mechanism underlying the up-regulation of YAP by HBx. Luciferase reporter gene assays revealed that the promoter region of YAP regulated by HBx was located at nt -232/+115 containing cyclic adenosine monophosphate response element-binding protein (CREB) element. Chromatin immunoprecipitation (ChIP) demonstrated that HBx was able to bind to the promoter of YAP, whereas it failed to work when CREB was silenced. Moreover, we confirmed that HBx activated the YAP promoter through CREB by electrophoretic mobility shift assay and luciferase reporter gene assays. Surprisingly, we found that YAP short interfering RNA was able to remarkably block the HBx-enhanced growth of hepatoma cells in vivo and in vitro.
CONCLUSION: YAP is a key driver gene in HBx-induced hepatocarcinogenesis in a CREB-dependent manner. YAP may serve as a novel target in HBV-associated HCC therapy.
Copyright © 2012 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22707013     DOI: 10.1002/hep.25899

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  83 in total

1.  Dynamic expression of ZNF382 and its tumor-suppressor role in hepatitis B virus-related hepatocellular carcinogenesis.

Authors:  Siwen Dang; Jingshi Zhou; Yijun Chen; Pu Chen; Meiju Ji; Bingyin Shi; Qi Yang; Peng Hou
Journal:  Oncogene       Date:  2019-02-25       Impact factor: 9.867

Review 2.  Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma.

Authors:  Amir Shlomai; Ype P de Jong; Charles M Rice
Journal:  Semin Cancer Biol       Date:  2014-01-20       Impact factor: 15.707

3.  TGF-β1 regulates the expression and transcriptional activity of TAZ protein via a Smad3-independent, myocardin-related transcription factor-mediated mechanism.

Authors:  Maria Zena Miranda; Janne Folke Bialik; Pam Speight; Qinghong Dan; Tony Yeung; Katalin Szászi; Stine F Pedersen; András Kapus
Journal:  J Biol Chem       Date:  2017-07-24       Impact factor: 5.157

4.  MicroRNA-15b/16 Attenuates Vascular Neointima Formation by Promoting the Contractile Phenotype of Vascular Smooth Muscle Through Targeting YAP.

Authors:  Fei Xu; Abu Shufian Ishtiaq Ahmed; Xiuhua Kang; Guoqing Hu; Fang Liu; Wei Zhang; Jiliang Zhou
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-08-20       Impact factor: 8.311

Review 5.  Molecular mechanisms of the preventable causes of cancer in the United States.

Authors:  Erica A Golemis; Paul Scheet; Tim N Beck; Eward M Scolnick; David J Hunter; Ernest Hawk; Nancy Hopkins
Journal:  Genes Dev       Date:  2018-06-26       Impact factor: 11.361

Review 6.  The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment.

Authors:  Randy Johnson; Georg Halder
Journal:  Nat Rev Drug Discov       Date:  2013-12-13       Impact factor: 84.694

7.  Hepatitis B virus X protein inhibits tumor suppressor miR-205 through inducing hypermethylation of miR-205 promoter to enhance carcinogenesis.

Authors:  Tao Zhang; Junping Zhang; Ming Cui; Fabao Liu; Xiaona You; Yumei Du; Yuen Gao; Shuai Zhang; Zhanping Lu; Lihong Ye; Xiaodong Zhang
Journal:  Neoplasia       Date:  2013-11       Impact factor: 5.715

8.  High expression of ubiquitin carboxyl-terminal hydrolase 22 is associated with poor prognosis in hepatitis B virus-associated liver cancer.

Authors:  Yong Liao; Xingsi Liang; Wenjin Liang; Zeming Li; Yan Wang; Lin Wang; Siqi Zhen; Bo Tang; Zhenran Wang
Journal:  Oncol Lett       Date:  2019-03-15       Impact factor: 2.967

9.  Hippo Cascade Controls Lineage Commitment of Liver Tumors in Mice and Humans.

Authors:  Shanshan Zhang; Jingxiao Wang; Haichuan Wang; Lingling Fan; Biao Fan; Billy Zeng; Junyan Tao; Xiaolei Li; Li Che; Antonio Cigliano; Silvia Ribback; Frank Dombrowski; Bin Chen; Wenming Cong; Lixin Wei; Diego F Calvisi; Xin Chen
Journal:  Am J Pathol       Date:  2018-01-31       Impact factor: 4.307

10.  Hepatitis B virus X protein mediates yes-associated protein 1 upregulation in hepatocellular carcinoma.

Authors:  Yuzhuo Wu; Junhe Zhang; Huaihong Zhang; Yufeng Zhai
Journal:  Oncol Lett       Date:  2016-07-20       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.